| Bioactivity | Axatilimab (SNDX-6352) is a humanized IgG4 antibody with high affinity to CSF-1R. Axatilimab can be used for the research of chronic graft versus host disease (cGVHD) and neoplastic diseases[1][2]. |
| Invitro | Axatilimab (SNDX-6352) 通过与 CSF-1R 结合并阻断其两种已知配体 CSF-1 和 IL-34 的激活来影响单核细胞和巨噬细胞的迁移、增殖、分化和存活。 |
| Name | Axatilimab |
| CAS | 2155851-88-8 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Arora M, et al. Phase 1 study of axatilimab (SNDX-6352), a CSF-1R humanized antibody, for chronic graft-versus-host disease after 2 or more lines of systemic treatment. Blood, 2020, 136: 1-2. [2]. Tiessen R, et al. First in human, single ascending dose study in healthy volunteers of SNDX-6352, a humanized IgG4 monoclonal antibody targeting colony stimulating factor-1 receptor (CSF-1R). J Immunother Cancer, 2016, 5: P505. |